Replies to post #45752 on Sunshine Biopharma Inc (SBFM)

[EOT]

October 17, 2019
Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada



For Immediate Release October 17, 2019
SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has initiated studies of Adva-27a in xenograft mice.

In these studies, specifically engineered mice which have developed tumors following injection with patient derived cancer cells are treated with Adva-27a to assess the ability of the drug to shrink the tumors.

Among the different types of patient derived cancer types being studied are Pancreatic Cancer, Breast Cancer, Small-Cell Lung Cancer and Uterine Sarcoma.

About Adva-27a
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. In vitro tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.